Jinling Pharmaceutical Co Ltd Asset Resilience Ratio
Jinling Pharmaceutical Co Ltd asset resilience ratio. Jinling Pharmaceutical Co Ltd (000919) has an Asset Resilience Ratio of 21.60% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 000919 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Jinling Pharmaceutical Co Ltd (1999–2024)
Asset resilience ratio of Jinling Pharmaceutical Co Ltd from 1999 to 2024. This chart shows how Jinling Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read how much debt does Jinling Pharmaceutical Co Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Jinling Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Jinling Pharmaceutical Co Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.30 Billion | 21.6% |
| Total Liquid Assets | CN¥1.30 Billion | 21.60% |
Asset Resilience Insights
- Good Liquidity Position: Jinling Pharmaceutical Co Ltd maintains a healthy 21.60% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Jinling Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jinling Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Jinling Pharmaceutical Co Ltd Asset Resilience Ratio by Year (1999–2024)
Jinling Pharmaceutical Co Ltd asset resilience ratio by year from 1999 to 2024. The table below shows the annual Asset Resilience Ratio data for Jinling Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.60% | CN¥706.05 Million ≈ $103.32 Million |
CN¥6.09 Billion ≈ $890.99 Million |
+9.78pp |
| 2023-12-31 | 1.81% | CN¥82.57 Million ≈ $12.08 Million |
CN¥4.55 Billion ≈ $665.88 Million |
-0.22pp |
| 2022-12-31 | 2.03% | CN¥92.35 Million ≈ $13.51 Million |
CN¥4.54 Billion ≈ $664.84 Million |
+2.00pp |
| 2021-12-31 | 0.03% | CN¥1.25 Million ≈ $183.06K |
CN¥4.45 Billion ≈ $650.83 Million |
0.00pp |
| 2020-12-31 | 0.03% | CN¥1.38 Million ≈ $201.35K |
CN¥4.28 Billion ≈ $626.82 Million |
-2.62pp |
| 2019-12-31 | 2.65% | CN¥110.28 Million ≈ $16.14 Million |
CN¥4.16 Billion ≈ $608.50 Million |
+1.30pp |
| 2018-12-31 | 1.35% | CN¥52.45 Million ≈ $7.67 Million |
CN¥3.88 Billion ≈ $568.49 Million |
-0.38pp |
| 2017-12-31 | 1.73% | CN¥66.76 Million ≈ $9.77 Million |
CN¥3.86 Billion ≈ $564.40 Million |
+0.66pp |
| 2016-12-31 | 1.08% | CN¥41.50 Million ≈ $6.07 Million |
CN¥3.86 Billion ≈ $564.53 Million |
-2.28pp |
| 2015-12-31 | 3.36% | CN¥129.18 Million ≈ $18.90 Million |
CN¥3.85 Billion ≈ $563.41 Million |
-1.52pp |
| 2014-12-31 | 4.87% | CN¥176.55 Million ≈ $25.83 Million |
CN¥3.62 Billion ≈ $530.04 Million |
+2.21pp |
| 2013-12-31 | 2.66% | CN¥87.97 Million ≈ $12.87 Million |
CN¥3.30 Billion ≈ $483.54 Million |
+1.74pp |
| 2012-12-31 | 0.93% | CN¥29.61 Million ≈ $4.33 Million |
CN¥3.20 Billion ≈ $468.10 Million |
-4.40pp |
| 2011-12-31 | 5.33% | CN¥157.59 Million ≈ $23.06 Million |
CN¥2.96 Billion ≈ $432.89 Million |
-1.70pp |
| 2010-12-31 | 7.02% | CN¥192.70 Million ≈ $28.20 Million |
CN¥2.74 Billion ≈ $401.50 Million |
-1.03pp |
| 2009-12-31 | 8.05% | CN¥197.68 Million ≈ $28.93 Million |
CN¥2.46 Billion ≈ $359.32 Million |
+3.66pp |
| 2008-12-31 | 4.39% | CN¥96.78 Million ≈ $14.16 Million |
CN¥2.20 Billion ≈ $322.34 Million |
-7.92pp |
| 2007-12-31 | 12.31% | CN¥291.34 Million ≈ $42.63 Million |
CN¥2.37 Billion ≈ $346.26 Million |
+5.66pp |
| 2006-12-31 | 6.65% | CN¥134.90 Million ≈ $19.74 Million |
CN¥2.03 Billion ≈ $296.92 Million |
+0.87pp |
| 2005-12-31 | 5.78% | CN¥106.44 Million ≈ $15.58 Million |
CN¥1.84 Billion ≈ $269.67 Million |
-2.63pp |
| 2004-12-31 | 8.40% | CN¥150.59 Million ≈ $22.04 Million |
CN¥1.79 Billion ≈ $262.23 Million |
-0.07pp |
| 2003-12-31 | 8.48% | CN¥138.64 Million ≈ $20.29 Million |
CN¥1.64 Billion ≈ $239.28 Million |
-3.30pp |
| 2002-12-31 | 11.78% | CN¥181.15 Million ≈ $26.51 Million |
CN¥1.54 Billion ≈ $225.01 Million |
-0.64pp |
| 2001-12-31 | 12.42% | CN¥175.89 Million ≈ $25.74 Million |
CN¥1.42 Billion ≈ $207.25 Million |
-15.10pp |
| 2000-12-31 | 27.52% | CN¥336.29 Million ≈ $49.21 Million |
CN¥1.22 Billion ≈ $178.84 Million |
+10.39pp |
| 1999-12-31 | 17.13% | CN¥200.60 Million ≈ $29.35 Million |
CN¥1.17 Billion ≈ $171.39 Million |
-- |
About Jinling Pharmaceutical Co Ltd
Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China and internationally. The company offers Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, multiple arteriosclerosis, phlebitis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, an… Read more